Detecting Cancer Patents (Class 435/6.14)
-
Patent number: 12043829Abstract: The present invention relates to the field of biotechnologies and in particular to the use of a nucleotide sequence having transcription promoter activity in prokaryotic and eukaryotic cell systems.Type: GrantFiled: December 22, 2022Date of Patent: July 23, 2024Assignee: UNIVERSITA' DEGLI STUDI DI BARI ALDO MOROInventors: René Massimiliano Marsano, Antonio Palazzo
-
Patent number: 12044682Abstract: A method for determining or diagnosing the presence or absence, or the risk of development, or the therapy control of autoimmune hepatitis in a subject is provided. In a method, the presence or absence of antibodies against the huntingtin interacting protein 1 related protein (HIP1R) or against immunoreactive peptides derived therefrom are analyzed, the presence of said antibodies is indicative for the presence, or the risk of development or for therapy control of autoimmune hepatitis of the subject. The use of the HIP1R or an immunoreactive peptide derived therefrom in the diagnosis, the risk assessment or therapy control of hepatitis diseases by determining the presence of antibodies against said HIP1R or immunoreactive peptide derived therefrom, may be helpful for differential diagnosis of autoimmune hepatitis.Type: GrantFiled: October 26, 2018Date of Patent: July 23, 2024Assignee: MEDIZINISCHE HOCHSCHULE HANNOVERInventors: Richard Taubert, Elmar Jaeckel, Niklas T. Baerlecken
-
Patent number: 12033695Abstract: Methods, systems, and devices for improved techniques for multi-level memory cell programming are described. A memory array may receive a first command to store a first logic state in a memory cell for storing three or more logic states. The memory array may apply, as part of an erase operation, a first pulse with a first polarity to a plurality of memory cells to store a second logic state different from the first logic state in the plurality of memory cells, where the plurality of memory cells includes the memory cell. The memory array may apply, as part of a write operation or as part of the erase operation, one or more second pulses with a second polarity to the memory cell to store the first logic state in the memory cell based on applying the first pulse.Type: GrantFiled: May 9, 2022Date of Patent: July 9, 2024Assignee: Micron Technology, Inc.Inventors: Innocenzo Tortorelli, Alessandro Sebastiani, Mattia Robustelli, Matteo Impalà
-
Patent number: 12031184Abstract: There is described herein a method of detecting the presence of DNA from cancer cells in a subject comprising: providing a sample of cell-free DNA from a subject; subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated, then optionally denaturing the sample; capturing cell-free methylated DNA using a binder selective for methylated polynucleotides; sequencing the captured cell-free methylated DNA; comparing the sequences of the captured cell-free methylated DNA to control cell-free methylated DNAs sequences from healthy and cancerous individuals and from individuals with distinct cancer types and subtypes; identifying the presence of DNA from cancer cells if there is a statistically significant similarity between one or more sequences of the captured cell-free methylated DNA and cell-free methylated DNAs sequences from cancerous individuals.Type: GrantFiled: July 11, 2018Date of Patent: July 9, 2024Assignees: University Health Network, Sinai Health SystemInventors: Daniel Diniz De Carvalho, Scott Victor Bratman, Rajat Singhania, Ankur Ravinarayana Chakravarthy, Shu Yi Shen
-
Patent number: 12035369Abstract: A method and apparatus for initial access based on a Channel Access Priority Class in a wireless communication system is provided. A wireless device receives, from a network, a specific Channel Access Priority Class (CAPC). A wireless device performs LBT procedure based on the specific CAPC. A wireless device attempts an uplink access to the RAN node after the LBT procedure, wherein the specific CAPC is included in a paging.Type: GrantFiled: February 13, 2020Date of Patent: July 9, 2024Assignee: LG ELECTRONICS INC.Inventors: Youngdae Lee, Sunghoon Jung
-
Patent number: 11998266Abstract: A method to apply a nerve inhibiting cloud surrounding a blood vessel includes creating a treatment plan, wherein the treatment plan prescribes application of the nerve inhibiting cloud towards at least a majority portion of a circumference of a blood vessel wall, and applying the nerve inhibiting cloud towards the majority portion of the circumference of the blood vessel wall for a time sufficient to inhibit a function of a nerve that surrounds the blood vessel wall.Type: GrantFiled: September 27, 2021Date of Patent: June 4, 2024Assignee: Otsuka Medical Devices Co., LtdInventor: Michael Gertner
-
Patent number: 11999992Abstract: Reagents for stabilizing the nucleic acids of a biological cell, compositions, kits and methods of use thereof are described. The stabilization reagents may prepare the nucleic acids within the biological cell for storage and preserve the representative population of the nucleic acids for later isolation and analysis.Type: GrantFiled: September 13, 2018Date of Patent: June 4, 2024Assignee: Bruker Cellular Analysis, Inc.Inventor: Jason M. McEwen
-
Patent number: 11995903Abstract: Systems and methods are disclosed for receiving one or more electronic slide images associated with a tissue specimen, the tissue specimen being associated with a patient and/or medical case, partitioning a first slide image of the one or more electronic slide images into a plurality of tiles, detecting a plurality of tissue regions of the first slide image and/or plurality of tiles to generate a tissue mask, determining whether any of the plurality of tiles corresponds to non-tissue, removing any of the plurality of tiles that are determined to be non-tissue, determining a prediction, using a machine learning prediction model, for at least one label for the one or more electronic slide images, the machine learning prediction model having been generated by processing a plurality of training images, and outputting the prediction of the trained machine learning prediction model.Type: GrantFiled: March 20, 2023Date of Patent: May 28, 2024Assignee: Paige.AI, Inc.Inventors: Brandon Rothrock, Christopher Kanan, Julian Viret, Thomas Fuchs, Leo Grady
-
Patent number: 11987849Abstract: This application relates to a composition for diagnosis of leptospirosis and a method for diagnosis of leptospirosis by real-time PCR. For example, the application relates to a pair of primers of SEQ ID NOS: 1 and 2 and a probe of SEQ ID NO: 3, a kit for diagnosis of leptospirosis, comprising the diagnostic composition, and a method for providing information for diagnosis of leptospirosis are provided. The composition and the method can specifically detect L. interrogans IS 1500 gene and exhibit excellent accuracy and sensitivity, compared to conventional well-known detection methods. Thus, the simple method through real-time PCR using the composition allows the quick and accurate diagnosis of leptospirosis.Type: GrantFiled: November 15, 2021Date of Patent: May 21, 2024Assignee: Industry-Academic Cooperation Foundation, Chosun UniversityInventors: Dong Min Kim, You Mi Lee, Choon Mee Kim
-
Patent number: 11989932Abstract: Systems and methods are provided for color-coded visualization to aid in diagnosis and prognosis of Alzheimer's disease (AD). The color-coded visualization mechanism can be driven by an integrated machine learning (ML) model, which can take as its inputs neuroimaging (e.g., magnetic resonance imaging (MRI), positron emission tomography (PET)) data, neuropsychological test scores, the cerebrospinal fluid (CSF) biomarker, and/or risk factors. With these inputs, the ML model can generate a color-coded visualization of the disease state.Type: GrantFiled: November 17, 2023Date of Patent: May 21, 2024Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEESInventors: Malek Adjouadi, Mohammad Eslami, Solale Tabarestani
-
Patent number: 11977075Abstract: A method and a kit are provided for predicting a favorable or a non-favorable response of a cancer patient to treatment with an immune checkpoint inhibitor by determining in a biological sample obtained from the cancer patient, before and after the treatment, the changes of the levels of factors/biomarkers generated by the cancer patient in response to said treatment, and a method for treatment of a cancer patient with an immune checkpoint inhibitor.Type: GrantFiled: December 13, 2018Date of Patent: May 7, 2024Assignee: Rappaport Family Institute for Research in the Medical SciencesInventor: Yuval Shaked
-
Patent number: 11971411Abstract: The present invention provides methods for screening and diagnosing prostate cancer based on a correlation between cancer cell growth, cancer lethality or recurrence and the expression level of ZFP36 or NEDD9 and PTEN in conjunction with ZFP36. The disclosure also provides methods for screening and diagnosing prostate cancer based on a correlation between cancer lethality and the genotype of rs1910301 SNP. Also provided are methods for treating prostate cancer comprising providing a treatment or monitoring based on the expression level of ZFP36, the expression level of NEDD9, and the expression level of ZFP36 in conjunction with PTEN levels or the genotype of rs1910301 SNP.Type: GrantFiled: January 20, 2017Date of Patent: April 30, 2024Assignees: DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Curtis Huttenhower, Travis Gerke, Christopher Sweeney, Lorelei Mucci, Gwo-Sho Mary Lee, Daniela Bornigen, Xiaodong Wang, Svitlana Tyekucheva, Kristina Jordahl
-
Patent number: 11965212Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.Type: GrantFiled: October 13, 2021Date of Patent: April 23, 2024Assignee: Quest Diagnostics Investments LLCInventors: Heather R. Sanders, Kevin Z. Qu, Charles M. Strom, Richard A. Bender
-
Patent number: 11957739Abstract: The present invention provides compositions and methods for treating cancers with reduced or absent CDH1 using a RHOA dominant negative polypeptide or biologically active fragment thereof, and/or a nucleic acid encoding a RHOA dominant negative polypeptide or biologically active fragment thereof.Type: GrantFiled: November 5, 2018Date of Patent: April 16, 2024Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Adam Bass, Haisheng Zhang
-
Patent number: 11953506Abstract: Methods for monitoring inflammation status of a subject comprise determining levels of at least one neutrophil activation marker, or at least three markers, in urine samples taken from the subject at multiple time points, wherein increased levels of the at least one neutrophil activation marker, or at least one of the markers, in a urine sample are indicative of or predictive of an exacerbation of inflammation and/or wherein decreased levels of the at least one neutrophil activation marker, or at least one of the markers, in a urine sample following an increase are indicative or predictive of recovery from, or successful treatment of, an exacerbation of inflammation. Corresponding systems, test kits and computer programs are provided.Type: GrantFiled: February 6, 2020Date of Patent: April 9, 2024Assignee: MOLOGIC LIMITEDInventors: Gita Parekh, Paul Davis
-
Patent number: 11944708Abstract: The present application provides methods of treating a CNS disorder (such as glioblastoma and epilepsy) in an individual, comprising systemically (e.g., intravenously or subcutaneously) administering to the individual an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, such as sirolimus or a derivative thereof) and an albumin, optionally further comprising administering a second agent (such as an anti-VEGF antibody, a proteasome inhibitor, or an alkylating agent).Type: GrantFiled: September 17, 2020Date of Patent: April 2, 2024Assignee: Abraxis BioScience, LLCInventors: Neil P. Desai, Shihe Hou
-
Patent number: 11948297Abstract: A racially unbiased mammogram analyzer includes an interface for receiving mammograms; a processor for extracting features of mammograms of general population; a processor for extracting features of mammograms of a specific race. In one embodiment, the general population mammogram features are represented by middle layers of a CNN and the race specific features are represented by the end layer of the CNN network. In one embodiment, the race specific layers of CNN change dynamically according to the race indication done explicitly. In one embodiment the race specific layers of CNN change dynamically according to the race indication given by race indication processor. In one embodiment, the race indications are computed by a network of parallel variational autoencoder networks. In one embodiment, the race indicator computes race specific information to the CNN and are provided by variational autoencoders.Type: GrantFiled: July 15, 2021Date of Patent: April 2, 2024Assignee: MedCognetics, Inc.Inventors: Timothy Cogan, Richard Stubblefield, Lakshman Tamil
-
Patent number: 11939574Abstract: The present invention provides ribosomal RNA origami nanostructures and in particular nanostructures comprising RNA staples, composition comprising such origami nanostructures as well as methods for manufacturing such origami structures.Type: GrantFiled: January 18, 2018Date of Patent: March 26, 2024Assignee: AUGMANITY NANO LTDInventors: Anastasia Shapiro, Ido Bachelet, Yaniv Amir, Erez Lavi, Danielle Karo-Atar
-
Patent number: 11926820Abstract: This disclosure describes methods and compositions for protein and peptide sequencing.Type: GrantFiled: September 11, 2020Date of Patent: March 12, 2024Assignee: Google LLCInventors: Annalisa Marie Pawlosky, Michael Gibbons, Shirley Jing Shao, Marc Berndl, Michelle Therese Hoerner Dimon, Ali Bashir, Lauren Schiff
-
Patent number: 11913072Abstract: Provided herein are methods and compositions to detect MET exon 14 skipping using RT-PCR, and methods of treating individuals with MET exon 14 deleted cancers.Type: GrantFiled: May 11, 2017Date of Patent: February 27, 2024Assignee: Roche Molecular Systems, Inc.Inventors: Cindy Cheung, Grantland Hillman, Xiaoju Max Ma, Chitra Manohar, Lily Wong
-
Patent number: 11913012Abstract: The present disclosure provides methods for generating induced cardiomyocytes and/or inducing a cardiomyocyte phenotype in cells in vivo or in vitro, such as by expression of ASCL1 or MYF6 and MYOCD. The present disclosure further provides gene-delivery vectors comprising one or more polynucleotides selected from ASCL1, MYF6, MYOCD, MEF2C, and TBX5. It further provides compositions comprising induced cardiomyocytes and provides methods of treating a heart condition, such as myocardial infarction. The disclosure also provides engineered myocardin proteins with an internal deletion, vectors encoding such engineered mycocardins, and methods of use thereof.Type: GrantFiled: March 24, 2021Date of Patent: February 27, 2024Assignee: Tenaya Therapeutics, Inc.Inventors: Huanyu Zhou, Laura Lombardi
-
Patent number: 11913939Abstract: Methods and systems for performing assays in compartmentalized nano-volumes to screen for functional bispecific or multispecific biologics, including: providing a plurality of at least two distinct types of cells, wherein two or more first-type cells are engineered to express substantially a single genetic-variant per cell for a bispecific or multispecific biologic in a secreted form, wherein two or more second-type cells are selected or engineered to produce a positive reporter molecule signal that is triggered by a functional variant of the said biologic expressed by a first-type cell; providing a plurality of compartmentalized nano-volumes, wherein two or more nano-volumes are each provided with substantially one first-type cell, and one or more second-type cell(s); incubating the said nano-volumes over a period of time to allow the expression and secretion of the said biologics inside the said nano-volumes; collecting data representing the positive reporter molecule signal triggered by secreted biologicsType: GrantFiled: April 2, 2021Date of Patent: February 27, 2024Assignee: Amberstone Biosciences, Inc.Inventors: George Guikai Wu, Yonglei Shang
-
Patent number: 11885733Abstract: Systems and methods for modeling and detecting white blood cell population dynamic for diagnosis and treatment, e.g., of acute coronary syndrome or leukocytosis.Type: GrantFiled: March 4, 2022Date of Patent: January 30, 2024Assignee: The General Hospital CorporationInventors: John M. Higgins, Anwesha Chaudhury
-
Patent number: 11884981Abstract: One aspect of the invention is a method for amplifying alpha globin genes HBA1, HBA2 and HBA12 in a single PCR tube to determine an HBA genotype of a subject. This method employs five primers selected to accurate and sensitively identify the HBA1, HBA2, and HBA12, a gene found at a higher frequency in citizens of Saudi Arabia, by accurately annealing to nucleic acids in a biological sample and simultaneously amplifying sequences encoding the alpha globin genes. This invention includes a procedure and required reagents for the amplification of alpha globin genes in a single PCR tube.Type: GrantFiled: May 27, 2021Date of Patent: January 30, 2024Assignee: Imam Abdulrahman Bin Faisal UniversityInventors: J. Francis Borgio, Sayed Abdulazeez, Fahd A. Al-Muhanna, Amein Kadhem Al-Ali
-
Patent number: 11879150Abstract: Treating colorectal cancer in a stage IV uses a systemic chemotherapy, either a FOLFOX regimen or a FOLFIRI regimen. However, a method of predicting which of the regimens is effective to an individual patient would be advantageous. Provided is a biomarker that indicates which of the regimens, the FOLFOX regimen or the FOLFIRI regimen, is advantageous to select for a patient having colorectal cancer. The biomarker is characterized by being a gain in the copy number of at least one region on human chromosomes among 7p15.3, 7q34, 8q24.1, 8q24.2, 8q24.1-q24.2, 9q34.3, 13q12.2, 13q14.11, 13q22.1, 13q32.2-q32.3, 13q34, 20q12, 20q13.13, 20q13.2, and 20q13.3. Using such a biomarker enables to determine which, the FOLFOX regimen or the FOLFIRI regimen, is more advantageously selected.Type: GrantFiled: September 23, 2016Date of Patent: January 23, 2024Assignees: YAKULT HONSHA CO., LTD., KINKI UNIVERSITYInventors: Kazuto Nishio, Yoshihiko Fujita
-
Patent number: 11872554Abstract: A microfluidic device includes an inlet port configured to receive a sample, a first reaction chamber fluidically coupled to the inlet port, a first pump fluidically coupled to the inlet port, a second pump fluidically coupled to a mixing chamber, a metering channel fluidically coupled to the first reaction chamber and to the mixing chamber, and one or more second reaction chambers fluidically coupled to the mixing chamber. The first pump is configured to move fluid from the inlet port to the first reaction chamber and from the first pump to the inlet port. The second pump is configured to move fluid from the second pump to the mixing chamber, from the first reaction chamber to the mixing chamber, and from the mixing chamber to the one or more second reaction chambers.Type: GrantFiled: March 9, 2020Date of Patent: January 16, 2024Assignee: ABBOTT DIAGNOSTICS SCARBOROUGH, INC.Inventors: Alexander Schenk zu Schweinsberg, Austin Matthew Derfus, Justin Davidson, Karthikeyan Kumaravadivelu, Maulik Vinod Patel, Olaf Piepenburg, Catherine Jean Greenwood, Oliver Nentwich
-
Patent number: 11873535Abstract: Described herein are methods and kits for authentication of botanical DNA fragments isolated from processed botanical products, including dietary supplements or nutraceutical compositions including botanical extracts.Type: GrantFiled: July 27, 2018Date of Patent: January 16, 2024Assignee: HERBALIFE INTERNATIONAL OF AMERICA, INC.Inventors: Zhengfei Lu, Silva Babajanian, Yanjun Zhang, Peter Chang, Gary Swanson, Maria Rubinsky
-
Patent number: 11873341Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: YQCVQGYRALHRGP (150 to 163) or SVCKMTHGKTRWTQP (166 to 180) on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.Type: GrantFiled: March 13, 2019Date of Patent: January 16, 2024Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Sergio Quezada
-
Patent number: 11866630Abstract: A quantum dot including a core including a first semiconductor nanocrystal including a Group III-V compound; and a semiconductor nanocrystal shell disposed on the core, the semiconductor nanocrystal shell including zinc, tellurium, and selenium, wherein the quantum dot does not include cadmium, and the semiconductor nanocrystal shell has a mole ratio of tellurium to selenium of less than about 0.025:1, a composition including the quantum dot, a quantum dot-polymer composite, a patterned layer including the composite, and an electronic device including the patterned layer.Type: GrantFiled: December 19, 2022Date of Patent: January 9, 2024Assignee: SAMSUNG DISPLAY CO., LTD.Inventors: Taekhoon Kim, Shin Ae Jun, Yong Wook Kim, Tae Gon Kim, Garam Park
-
Patent number: 11851709Abstract: The present invention refers to an in vitro method for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer comprising the detection and/or quantification of the expression of HER2 in an isolated biological sample of the patient, either (1) before or (2) before and during the anti-HER2 therapy in the absence of chemotherapy treatment. The present invention also refers to the use of a gene expression product of HER2 as a as an in vitro marker for determining the efficacy of anti-HER2 therapy in the absence of chemotherapy in a patient with HER2+ breast cancer, or alternatively as an in vitro marker for deciding or recommending whether to initiate an alternative medical regime to anti-HER2 therapy without chemotherapy in a patient with HER2+ breast cancer.Type: GrantFiled: December 7, 2016Date of Patent: December 26, 2023Assignees: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA DE VALL D'HEBRON, FUNDACIÓN SOLTI, FUNDACIÓN PARA EL FOMENTO DE LA INVESTIGACIÓN SANITARIA Y BIOMÉDICA DE LA COMUNITAT VALENCIANA, HOSPITAL CLÍNIC DE BARCELONAInventors: Aleix Prat Aparicio, Javier Cortés Castán, Antonio Llombart Cussac
-
Patent number: 11847817Abstract: Methods and systems for automated assessment of spermatogenesis. Embodiments disclosed herein relate to drug development and testicular toxicity in safety evaluation studies, and more particularly to automatic assessment of spermatogenesis through a staging of seminiferous tubules using Artificial Intelligence/deep learning methods. A method disclosed herein includes detecting the seminiferous tubules by analyzing a testes tissue specimen and mapping the seminiferous tubules to detect and segment germ cells. The method includes classifying the seminiferous tubules into respective stages based on the segmented germ cells. The method further includes categorizing the seminiferous tubules into a normal category and an abnormal category based on the segmented germ cells. The method further includes categorizing the testes tissue specimen into the normal category and the abnormal category based on the classification of the seminiferous tubules for toxicity analysis.Type: GrantFiled: September 16, 2020Date of Patent: December 19, 2023Assignee: AIRAMATRIX PRIVATE LIMITEDInventors: Rohit, Pranab Samanta
-
Patent number: 11845975Abstract: The present disclosure provides a body fluid extract comprising micro RNA.Type: GrantFiled: December 10, 2019Date of Patent: December 19, 2023Assignee: Craif Inc.Inventors: Takao Yasui, Daiki Takeshita, Yoshinobu Baba
-
Patent number: 11845080Abstract: A heating system for an EWOD device using a single, spatially-structured temperature control element, used to create a zone with a specific temperature profile. The heating system uses multiple contact regions between the temperature control element and the device. One or more contact regions are separated from the temperature control element by one or more thermally resistive layers that restrict heat flow from the temperature control element to the device, and further restrict lateral flow of heat between adjacent contact regions. The heating system can use materials with different thermal resistance to alter the heat flow to different regions. The spatial location of the contact regions is also used to determine the temperature profile within the device. The device has an optional temperature control element which offsets the low temperature point from the inlet temperature. This invention includes methods to process multiple droplets within the multiple temperature zones.Type: GrantFiled: December 6, 2017Date of Patent: December 19, 2023Assignee: Sharp Life Science (EU) LimitedInventor: Phillip Mark Shryane Roberts
-
Patent number: 11840735Abstract: This document provides methods and materials for identifying malignant skin lesions (e.g., malignant pigmented skin lesions). For example, methods and materials for using quantitative PCR results and correction protocols to reduce the impact of basal keratinocyte contamination on the analysis of test sample results to identify malignant skin lesions are provided.Type: GrantFiled: July 22, 2019Date of Patent: December 12, 2023Assignee: Mayo Foundation for Medical Education and ResearchInventors: Alexander Meves, Ekaterina M. Nikolova
-
Patent number: 11840733Abstract: The present invention relates to a method for predicting the prognosis of a breast cancer patient. More specifically, to provide information needed to predict the prognosis of a breast cancer patient, the method for predicting the prognosis of breast cancer including the following steps of the present invention comprises: (a) obtaining a biological sample from a breast cancer patient; (b) measuring the mRNA expression level of matrix metallopeptidase 11 (MMP11) and the mRNA expression level of cluster of differentiation 2 (CD2) from patient information or the sample of step (a); (c) normalizing the gene mRNA expression levels selected and measured in step (b); and (d) predicting the prognosis of breast cancer by combining the gene expression levels normalized in step (c), wherein overexpression of the MMP11 indicates a bad prognosis, and overexpression of CD2 indicates a good prognosis.Type: GrantFiled: November 21, 2017Date of Patent: December 12, 2023Assignee: GENCURIX INC.Inventors: Sang Rae Cho, Young Ho Moon, Jin Il Han, Young Kee Shin
-
Patent number: 11828768Abstract: The present invention relates to a device and a method for qualitative and quantitative analysis of heavy metals and more particularly provides a device and a method for qualitative and quantitative analysis of heavy metals utilizing a rotary disc system.Type: GrantFiled: October 25, 2018Date of Patent: November 28, 2023Inventors: Byung Hyun Park, Byoung Hyoun Kim, Dong Hyun Kim, Su Youn Han
-
Patent number: 11821040Abstract: The invention provides in vitro methods of determining whether an individual has a pre-cancer or cancer comprising determining the presence or absence of one or more methylation markers of a methylation marker set in a urine sample of said individual; and determining whether the individual has pre-cancer or cancer based on the detection of the presence or absence of said one or more methylation markers in the urine sample, wherein the presence of said one or more methylation markers indicates that the individual has pre-cancer or cancer. The invention further provides methods for typing pre-cancer or cancer based on the the presence or absence of one or more methylation markers of a methylation marker set in a urine sample.Type: GrantFiled: March 31, 2017Date of Patent: November 21, 2023Assignee: Nanomed Diagnostics BVInventors: Willem Frederik Rurup, Loes Irene Segerink, Roderik Adriaan Kraaijenhagen, Herbert Michael Pinedo, Albert Van Den Berg, Renske Daniëla Maria Steenbergen, Jacobus Adrianus Nieuwenhuijzen, Idris Bahce, Geert Kazemier
-
Patent number: 11821037Abstract: By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with chronic allograft nephropathy and/or interstitial fibrosis and tubular atrophy CAN/IFTA and subtypes thereof. These genes sets are useful for diagnosis, prognosis, monitoring and/or subtyping of CAN/IFTA.Type: GrantFiled: February 27, 2020Date of Patent: November 21, 2023Assignee: THE SCRIPPS RESEARCH INSTITUTEInventors: Daniel R. Salomon, Sunil M. Kurian, Steven R. Head
-
Patent number: 11821046Abstract: Disclosed are nucleic acid oligomers, including amplification oligomers, capture probes, and detection probes, for detection of Zika virus nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.Type: GrantFiled: September 25, 2020Date of Patent: November 21, 2023Assignee: Gen-Probe IncorporatedInventors: Kui Gao, Jeffrey M. Linnen
-
Patent number: 11807892Abstract: One aspect of the invention provides a system for drug discovery, drug development, drug screening, or drug validation. The system includes: a sample chamber comprising a target protein and a drug candidate that may interfere with the target protein in the sample chamber, wherein the sample chamber is configured to: detect one or more of the following: (a) interference between the drug candidate the target protein and/or (b) one or more dynamics of the drug candidate on the target protein, wherein the one or more dynamics comprise affinity of the drug candidate to the target protein, and select the drug candidate if one or more desirable dynamics is detected. The system includes one or more immobilized surfaces and is configured to detect interactions between the drug candidate and the target protein at the single-molecule level.Type: GrantFiled: April 16, 2020Date of Patent: November 7, 2023Assignee: Nanobiosym, Inc.Inventor: Anita Goel
-
Patent number: 11807895Abstract: A method for detecting oncogenic growth and viability, and/or degree of cellular transformation and/or identifying an agent that inhibits cellular transformation is disclosed. The method including: providing a cellular sample, such as a sample of cells obtained from a subject or a cell line; culturing the cellular sample in low attachment conditions; and detecting growth and7or cell viability of the sample, wherein increased growth relative and/or viability relative to a control or control level indicative of basal growth and/or viability indicates cellular transformation. In some embodiments, the method includes introducing a n expression vector into cells of the cellular sample, wherein the expression vector comprises a gene product expression sequence being tested for transformation ability. In some embodiments the cellular sample is contacted with a test agent and growth and/or cell viability of the sample is determined to determine if the agent inhibits transformation.Type: GrantFiled: March 24, 2016Date of Patent: November 7, 2023Assignees: THE BROAD INSTITUTE, INC., DANA FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Asaf Rotem, Kevin Struhl, Paul Blainey, Liyi Xu
-
Patent number: 11786872Abstract: The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; and (b) sorting the genetic elements which express the gene product having the desired activity; wherein at least one step is under microfluidic control. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention.Type: GrantFiled: May 1, 2020Date of Patent: October 17, 2023Assignees: UNITED KINGDOM RESEARCH AND INNOVATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Andrew David Griffiths, David A. Weitz, Darren Roy Link, Keunho Ahn, Jerome Bibette
-
Patent number: 11788129Abstract: A GAPDH nucleic acid detection kit includes a primer set for detecting GAPDH nucleic acid. The primer set for detecting GAPDH nucleic acid includes a forward inner primer for GAPDH nucleic acids, a forward outer primer for GAPDH nucleic acids, a backward inner primer for GAPDH nucleic acids and a backward outer primer for GAPDH nucleic acids. The primer set for detecting GAPDH nucleic acid is used in a loop-mediated isothermal amplification (LAMP).Type: GrantFiled: December 10, 2021Date of Patent: October 17, 2023Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Min-Yuan Chou, Kuang-Chi Cheng, Ming-Hua Yang, Jiun-Lin Guo
-
Patent number: 11788084Abstract: The present invention relates to the field of biotechnologies and in particular to the use of a nucleotide sequence having transcription promoter activity in prokaryotic and eukaryotic cell systems.Type: GrantFiled: December 16, 2019Date of Patent: October 17, 2023Assignee: UNIVERSITA' DEGLI STUDI DI BARI ALDO MOROInventors: René Massimiliano Marsano, Antonio Palazzo
-
Patent number: 11781153Abstract: A new use of OsDGD2? gene in breeding of male sterile rice materials is disclosed. The OsDGD2? gene deletion mutant created by technologies such as CRISPR/Cas9 gene editing is stable in male sterility, with no negative impact on female fertility and other traits (such as photosynthesis), making it uniquely superior in cross breeding and utilization of heterosis.Type: GrantFiled: July 3, 2020Date of Patent: October 10, 2023Assignee: Zhejiang UniversityInventors: Qingyao Shu, Rasbin Basnet
-
Patent number: 11760995Abstract: Provided is a PCR primer pair, comprising: a first primer and a second primer, wherein the first primer comprises a first specific sequence and a first random sequence; the first specific sequence is located on 3? end of the first primer, and the first random sequence is located on 5? end of the first primer; the second primer comprises a second specific sequence and a second random sequence, the second specific sequence is located on 3? end of the second primer, and the second random sequence is located on 5? end of the second primer; moreover, the first specific sequence and the second specific sequence are an upstream primer and a downstream primer directed to a target sequence respectively, and the first random sequence and the second random sequence are inverse complementary.Type: GrantFiled: June 20, 2017Date of Patent: September 19, 2023Assignee: MGI TECH CO., LTD.Inventors: Lin Yang, Ya Gao, Guodong Huang, Yicong Wang, Yuqian Wang, Yanyan Zhang, Fang Chen, Na Zhong, Hui Jiang, Xun Xu
-
Patent number: 11753616Abstract: The present application is to provide a composition and method for stabilizing and maintaining the viability of hardy microorganisms from sample collection to downstream analysis. In particular, there is a method for preserving viable hardy bacteria, such as Mycobacteria, Bacillus anthracis, or Clostridium difficile, in a biological sample, comprising contacting the biological sample with a stabilization composition, wherein the stabilization composition comprises a chelating agent, a denaturing, a salt and has a pH between about 6 and about 11.Type: GrantFiled: May 27, 2015Date of Patent: September 12, 2023Assignee: DNA Genotek, Inc.Inventors: H. Chaim Birnboim, Cassandra Kelly-Cirino, Bitapi Ray, Jacques Oscar Everard Niles, Olle Maarten de Bruin
-
Patent number: 11747335Abstract: Compositions and methods are provided for determining platelet reactivity where the levels of Fc?RIIa on the surface of platelets is measured and if the levels of Fc?RIIa are greater than a reference value, the platelets have enhanced reactivity.Type: GrantFiled: October 30, 2019Date of Patent: September 5, 2023Assignee: University of Vermont And State Agriculture CollegeInventor: David Schneider
-
Patent number: 11737993Abstract: The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).Type: GrantFiled: August 26, 2019Date of Patent: August 29, 2023Assignee: VANDA PHARMACEUTICALS INC.Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
-
Patent number: 11738033Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.Type: GrantFiled: May 11, 2021Date of Patent: August 29, 2023Assignee: EIRGEN PHARMA LTD.Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell